RS57594B1 - Derivati pirazina za sprečavanje ili lečenje ataksičnog poremećaja - Google Patents
Derivati pirazina za sprečavanje ili lečenje ataksičnog poremećajaInfo
- Publication number
- RS57594B1 RS57594B1 RS20180927A RSP20180927A RS57594B1 RS 57594 B1 RS57594 B1 RS 57594B1 RS 20180927 A RS20180927 A RS 20180927A RS P20180927 A RSP20180927 A RS P20180927A RS 57594 B1 RS57594 B1 RS 57594B1
- Authority
- RS
- Serbia
- Prior art keywords
- hydroxypyridazin
- ethyl
- hydroxy
- trifluoromethyl
- pyridazin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1403944.0A GB201403944D0 (en) | 2014-03-06 | 2014-03-06 | New use |
| PCT/GB2015/050654 WO2015132608A1 (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
| EP15709324.6A EP3113778B1 (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS57594B1 true RS57594B1 (sr) | 2018-11-30 |
Family
ID=50554599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20180927A RS57594B1 (sr) | 2014-03-06 | 2015-03-06 | Derivati pirazina za sprečavanje ili lečenje ataksičnog poremećaja |
Country Status (32)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| US10118917B2 (en) | 2014-04-29 | 2018-11-06 | E I Du Pont De Nemours And Company | Pyridazinone herbicides |
| TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
| US11213030B2 (en) | 2017-06-30 | 2022-01-04 | Fmc Corporation | 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides |
| CN112569217B (zh) * | 2019-09-30 | 2022-04-22 | 厦门大学 | 戊酸衍生物在治疗遗传性小脑共济失调中的应用 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| CA3209781A1 (en) | 2021-03-01 | 2022-09-09 | Takeda Pharmaceuticals Company Limited | Use of luvadaxistat for the treatment of cognitive impairment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE321553T1 (de) * | 1998-06-10 | 2006-04-15 | Meiji Seika Kaisha | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie |
| WO2003047558A2 (en) * | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
-
2014
- 2014-03-06 GB GBGB1403944.0A patent/GB201403944D0/en not_active Ceased
-
2015
- 2015-03-05 TW TW104106995A patent/TW201534591A/zh unknown
- 2015-03-06 US US15/123,796 patent/US20170014407A1/en not_active Abandoned
- 2015-03-06 GE GEAP201514284A patent/GEP20196984B/en unknown
- 2015-03-06 TR TR2018/09537T patent/TR201809537T4/tr unknown
- 2015-03-06 HR HRP20181082TT patent/HRP20181082T1/hr unknown
- 2015-03-06 MX MX2016010524A patent/MX2016010524A/es unknown
- 2015-03-06 WO PCT/GB2015/050654 patent/WO2015132608A1/en not_active Ceased
- 2015-03-06 DK DK15709324.6T patent/DK3113778T3/en active
- 2015-03-06 KR KR1020167027639A patent/KR20160126081A/ko not_active Withdrawn
- 2015-03-06 EA EA201691566A patent/EA036438B1/ru unknown
- 2015-03-06 MY MYPI2016703081A patent/MY202127A/en unknown
- 2015-03-06 SI SI201530291T patent/SI3113778T1/en unknown
- 2015-03-06 UA UAA201608758A patent/UA123352C2/uk unknown
- 2015-03-06 SG SG11201607106YA patent/SG11201607106YA/en unknown
- 2015-03-06 SM SM20180367T patent/SMT201800367T1/it unknown
- 2015-03-06 RS RS20180927A patent/RS57594B1/sr unknown
- 2015-03-06 MA MA39315A patent/MA39315A1/fr unknown
- 2015-03-06 ES ES15709324.6T patent/ES2676905T3/es active Active
- 2015-03-06 CN CN201580012352.1A patent/CN106102743A/zh active Pending
- 2015-03-06 LT LTEP15709324.6T patent/LT3113778T/lt unknown
- 2015-03-06 AU AU2015225954A patent/AU2015225954B2/en not_active Ceased
- 2015-03-06 EP EP15709324.6A patent/EP3113778B1/en active Active
- 2015-03-06 PL PL15709324T patent/PL3113778T3/pl unknown
- 2015-03-06 CA CA2940342A patent/CA2940342A1/en not_active Abandoned
- 2015-03-06 JP JP2016555645A patent/JP6510549B2/ja not_active Expired - Fee Related
- 2015-03-06 PT PT157093246T patent/PT3113778T/pt unknown
-
2016
- 2016-07-06 ZA ZA2016/04611A patent/ZA201604611B/en unknown
- 2016-08-23 IL IL247435A patent/IL247435A0/en active IP Right Grant
- 2016-08-25 CL CL2016002151A patent/CL2016002151A1/es unknown
- 2016-09-06 PH PH12016501751A patent/PH12016501751A1/en unknown
-
2018
- 2018-08-10 CY CY20181100843T patent/CY1120573T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3113778B1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| Schallert et al. | Disentangling multiple types of recovery from brain injury | |
| Toda et al. | Cigarette smoking impairs nitric oxide-mediated cerebral blood flow increase: Implications for Alzheimer's disease | |
| US20220040150A1 (en) | Intravenous dmt administration method for dmt-assisted psychotherapy | |
| JP5605659B2 (ja) | 細胞保護剤 | |
| Mair et al. | Memory enhancement with event-related stimulation of the rostral intralaminar thalamic nuclei | |
| Ewing et al. | Environmental enrichment facilitates cocaine abstinence in an animal conflict model | |
| JP2008542417A (ja) | 進行性ミオクローヌスてんかんに特徴付けられる疾患の治療用ブリバラセタムの使用 | |
| Nolan et al. | Purkinje cell loss by OX7-saporin impairs acquisition and extinction of eyeblink conditioning | |
| Freeman et al. | Eyeblink conditioning in rats using pontine stimulation as a conditioned stimulus | |
| Eckley et al. | Acepromazine and chlorpromazine as pharmaceutical-grade alternatives to chlorprothixene for pupillary light reflex imaging in mice | |
| Sawa et al. | Regulatory influence of amygdaloid nuclei upon the unitary activity in ventromedial nucleus of hypothalamus | |
| JP7545714B2 (ja) | 神経障害の治療剤 | |
| Barr et al. | Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats | |
| HK1230925A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| US20080318926A1 (en) | Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives | |
| Nakamura et al. | Depression induced by low-frequency repetitive transcranial magnetic stimulation to ventral medial frontal cortex in monkeys | |
| Masseck et al. | The optokinetic reaction in foveate and afoveate geckos | |
| Yao et al. | Transfer of classical eyeblink conditioning with electrical stimulation of mPFC or tone as conditioned stimulus in guinea pigs | |
| Poulos et al. | Disruption of cerebellar cortical inhibition in the absence of learning promotes sensory-evoked eyeblink responses. | |
| Lloyd et al. | The behavioral physiology and antidepressant mechanisms of electroconvulsive shock | |
| Zyss et al. | The behavioural effects of the transcranial magnetic brain stimulation (TMS) in a rat: a comparison with electroshocks | |
| Brumley | The ontogeny of interlimb coordination during serotonin-induced hindlimb stepping in the perinatal rat | |
| Cole | Highlights from the 14th International Congress of Parkinson´ s Disease and Movement Disorders: Future treatments | |
| Hunter | Glutamate and escape performance in a neurometabolic stress conception of helplessness |